Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Frequently asked questions
What sector does Scandion Oncology A/S (SCOL) operate in?
Scandion Oncology A/S belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Scandion Oncology A/S (SCOL) current stock price?
As of the latest data, Scandion Oncology A/S stock price is SEK 0.00, with a previous close of SEK 0.00.
What is Scandion Oncology A/S (SCOL) current market capitalization?
Scandion Oncology A/S market cap is approximately 962.52 thousand.
What is Scandion Oncology A/S (SCOL) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.24.
Does Scandion Oncology A/S (SCOL) pay dividends?
No. Scandion Oncology A/S does not pay a dividend.
What is Scandion Oncology A/S (SCOL) beta (volatility) score?
Scandion Oncology A/S has a beta of 1.858, suggesting it is more volatile than the market.
